FDMT vs ATTO
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
FDMT · 4D Molecular Therapeutics$12.25 ▲ 8.89%
ATTO · Attovia Therapeutics$15.27 ▲ 1.80%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- FDMT +19.2%
- ATTO -30.3%
Head to head
| Metric | FDMT | ATTO |
|---|---|---|
| Price | $12.25 | $15.27 |
| Change today | ▲ 8.89% | ▲ 1.80% |
| Market cap | $676.74M | $697.09M |
| Return, 3 months | +10.0% | -23.0% |
| Return, year to date | +63.3% | – |
| Return, 1 year | +16.7% | – |
| P/E (TTM) | -4.7 | -9.9 |
| P/B | 1.7 | -4.8 |
| P/E percentile vs own 5y | 42nd | 75th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | +25,106.7% | – |
| Net profit growth (YoY) | -33.4% | -43.3% |
| Gross margin | – | – |
| Operating margin | -214.2% | -4,232.9% |
| Net margin | -194.7% | -3,910.0% |
| Return on equity | -43.3% | – |
| Analyst target vs. price | +140.8% | +160.3% |
| Analyst buy share | 86% | 100% |
| RSI (14) | 49 | 45 |
| 30-day volatility | 79.8% | 63.1% |
| Max drawdown, 1 year | -41.4% | -46.3% |
| Trend read | Leaning bullish | Leaning bullish |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ATTO is the largest of the group by market value.
- ATTO carries the lowest trailing P/E.
- FDMT keeps the most profit per dollar of sales.
- ATTO has been the calmest stock over the last 30 days.